Rhythm Pharmaceuticals, Inc.
RYTMNASDAQHealthcare● Active
$85.93
$-0.48(-0.55%)
Market Cap$5.9B
P/E Ratio—
52W High$122.2
52W Low$60.7
Rhythm Pharmaceuticals, Inc. (RYTM) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RYTM · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.20B) | ($0.26B) | ($0.18B) | ($0.18B) | ($0.07B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.07B | $0.04B | $0.03B | $0.02B | $0.02B |
| Change in Working Capital | ($0.00B) | $0.01B | $0.00B | ($0.02B) | $0.00B |
| Net Cash from Operations | ($0.12B) | ($0.11B) | ($0.14B) | ($0.17B) | ($0.15B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | ($0.01B) |
| Purchases of Investments | ($0.35B) | ($0.27B) | ($0.35B) | ($0.25B) | ($0.52B) |
| Sales of Investments | $0.25B | $0.26B | $0.35B | $0.28B | $0.36B |
| Net Cash from Investing | ($0.14B) | ($0.05B) | ($0.01B) | $0.03B | ($0.06B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | ($0.01B) | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.22B | $0.19B | $0.07B | $0.21B | $0.17B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.12B) | ($0.11B) | ($0.14B) | ($0.18B) | ($0.15B) |
| FCF Margin %(computed) | -61.46% | -87.51% | -175.91% | -751.79% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Rhythm Pharmaceuticals, Inc. data
About Rhythm Pharmaceuticals, Inc. (RYTM) Cash Flow Statement
Rhythm Pharmaceuticals, Inc. generated operating cash flow of ($0.12B) and free cash flow of ($0.12B) for 2025 — a FCF margin of -61.46%. Capital expenditure was ($0.00B).
Frequently asked questions
RYTM · 4 questionsRhythm Pharmaceuticals, Inc. generated free cash flow of ($0.12B) for 2025, down 2.4% year-over-year.
RYTM free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10